دورية أكاديمية
أعرض في EDS

Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia.

التفاصيل البيبلوغرافية
العنوان: Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia.
المؤلفون: Cassidy-Seyoum SA; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.; Department of Health Ethics and Society, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands., Chheng K; Faculty of Tropical Medicine, Mahidol Oxford Research Unit, Mahidol University, Bangkok, Thailand., Chanpheakdey P; Faculty of Tropical Medicine, Mahidol Oxford Research Unit, Mahidol University, Bangkok, Thailand., Meershoek A; Department of Health Ethics and Society, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands., Hsiang MS; Institute for Global Health Sciences, Malaria Elimination Initiative, University of California San Francisco, San Francisco, California, United States of America.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.; Department of Pediatrics, Division of Pediatric Infectious Diseases, University of California San Francisco, San Francisco, California, United States of America., von Seidlein L; Faculty of Tropical Medicine, Mahidol Oxford Research Unit, Mahidol University, Bangkok, Thailand.; Nuffield Department of Medicine, Center for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom., Tripura R; Faculty of Tropical Medicine, Mahidol Oxford Research Unit, Mahidol University, Bangkok, Thailand.; Nuffield Department of Medicine, Center for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom., Adhikari B; Faculty of Tropical Medicine, Mahidol Oxford Research Unit, Mahidol University, Bangkok, Thailand.; Nuffield Department of Medicine, Center for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom., Ley B; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.; Division of Education, Menzies School of Health Research, Charles Darwin University, Darwin, Australia., Price RN; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.; Faculty of Tropical Medicine, Mahidol Oxford Research Unit, Mahidol University, Bangkok, Thailand.; Nuffield Department of Medicine, Center for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom., Lek D; National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia.; National Institute of Public Health, School of Public Health, Phnom Penh, Cambodia., Engel N; Department of Health Ethics and Society, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands., Thriemer K; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
المصدر: PLOS global public health [PLOS Glob Public Health] 2024 Jul 19; Vol. 4 (7), pp. e0003476. Date of Electronic Publication: 2024 Jul 19 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 9918283779606676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-3375 (Electronic) Linking ISSN: 27673375 NLM ISO Abbreviation: PLOS Glob Public Health Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, California : Public Library of Science, [2021]-
مستخلص: Plasmodium vivax remains a challenge for malaria elimination since it forms dormant liver stages (hypnozoites) that can reactivate after initial infection. 8-aminoquinolone drugs kill hypnozoites but can cause severe hemolysis in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. The STANDARD G6PD test (Biosensor) is a novel point-of-care diagnostic capable of identifying G6PD deficiency prior to treatment. In 2021, Cambodia implemented the Biosensor to facilitate radical cure treatment for vivax malaria. To assess the Biosensor's implementation after its national rollout, a mixed-methods study was conducted in eight districts across three provinces in Cambodia. Interviews, focus group discussions, and observations explored stakeholders' experiences with G6PD testing and factors influencing its implementation. Quantitative data illustrative of test implementation were gathered from routine surveillance forms and key proportions derived. Qualitative data were analyzed thematically. The main challenge to implementing G6PD testing was that only 49.2% (437/888) of eligible patients reached health centers for G6PD testing following malaria diagnosis by community health workers. Factors influencing this included road conditions and long distances to the health center, compounded by the cost of seeking further care and patients' perceptions of vivax malaria and its treatment. 93.9% (790/841) of eligible vivax malaria patients who successfully completed referral (429/434) and directly presented to the health center (360/407) were G6PD tested. Key enabling factors included the test's acceptability among health workers and their understanding of the rationale for testing. Only 36.5% (443/1213) of eligible vivax episodes appropriately received primaquine. 70.5% (165/234) of female patients and all children under 20 kilograms never received primaquine. Our findings suggest that access to radical cure requires robust infrastructure and income security, which would likely improve referral rates to health centers enabling access. Bringing treatment closer to patients, through community health workers and nuanced community engagement, would improve access to curative treatment of vivax malaria.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Cassidy-Seyoum et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Lancet Reg Health Southeast Asia. 2022 Dec 13;9:100128. (PMID: 37383038)
Malar J. 2016 Nov 2;15(1):523. (PMID: 27806717)
Malar J. 2020 Jan 2;19(1):2. (PMID: 31898498)
Pathogens. 2023 May 08;12(5):. (PMID: 37242359)
Nanobiomedicine (Rij). 2015;2:. (PMID: 26594252)
Int J Environ Res Public Health. 2021 Feb 18;18(4):. (PMID: 33670471)
Niger Med J. 2013 Mar;54(2):115-22. (PMID: 23798798)
BMJ Open. 2017 Mar 8;7(3):e012973. (PMID: 28274962)
Elife. 2021 Feb 05;10:. (PMID: 33543710)
J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686)
Lancet. 2019 Jul 27;394(10195):332-343. (PMID: 31229233)
Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):97-107. (PMID: 27708187)
Malar J. 2024 Feb 23;23(1):56. (PMID: 38395925)
Lancet Glob Health. 2024 Mar;12(3):e467-e477. (PMID: 38365417)
Pathogens. 2023 Apr 27;12(5):. (PMID: 37242320)
BMC Public Health. 2022 Sep 6;22(1):1689. (PMID: 36068516)
J Hum Genet. 2005;50(9):468-472. (PMID: 16136268)
J Health Popul Nutr. 2009 Feb;27(1):4-13. (PMID: 19248643)
Implement Sci. 2014 Jan 02;9:2. (PMID: 24383661)
PLoS One. 2014 Dec 26;9(12):e116143. (PMID: 25541721)
Malar J. 2016 Feb 05;15:64. (PMID: 26850000)
Implement Sci. 2012 Jan 23;7:5. (PMID: 22269037)
BMC Health Serv Res. 2016 Oct 19;16(1):591. (PMID: 27756282)
PLoS One. 2011;6(12):e28357. (PMID: 22164279)
Am J Trop Med Hyg. 2020 Sep;103(3):1094-1099. (PMID: 32524950)
Malar J. 2010 Apr 14;9:95. (PMID: 20398262)
BMJ. 2010 Mar 05;340:c930. (PMID: 20207689)
J Theor Biol. 2013 Jan 7;316:25-34. (PMID: 22959914)
Lancet. 2019 Sep 14;394(10202):929-938. (PMID: 31327563)
Malar J. 2014 Dec 17;13:502. (PMID: 25519710)
N Engl J Med. 2019 Jan 17;380(3):229-241. (PMID: 30650326)
Malar J. 2016 Mar 15;15:163. (PMID: 26979286)
BMJ. 2019 May 10;365:l2068. (PMID: 31076440)
Malar J. 2019 Jan 23;18(1):20. (PMID: 30674319)
Kolner Z Soz Sozpsychol. 2017;69(Suppl 2):107-131. (PMID: 28989188)
Malar J. 2016 May 20;15(1):282. (PMID: 27206729)
WHO South East Asia J Public Health. 2017 Sep;6(2):60-68. (PMID: 28857064)
Malar J. 2022 Oct 4;21(1):282. (PMID: 36195916)
Malar J. 2022 Jul 21;21(1):224. (PMID: 35864543)
PLoS Med. 2012;9(9):e1001306. (PMID: 22973183)
Malar J. 2016 Feb 27;15:126. (PMID: 26921263)
PLoS Med. 2014 Jan;11(1):e1001590. (PMID: 24465186)
Malar J. 2021 Mar 23;20(1):164. (PMID: 33757538)
PLoS Med. 2012;9(11):e1001339. (PMID: 23152723)
Glob Public Health. 2017 Sep;12(9):1077-1091. (PMID: 26457440)
PLoS Med. 2010 Nov 02;7(11):e1000360. (PMID: 21072245)
PLoS Negl Trop Dis. 2021 Aug 12;15(8):e0009649. (PMID: 34383774)
J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660)
PLoS Negl Trop Dis. 2023 Oct 12;17(10):e0011652. (PMID: 37824592)
Malar J. 2015 Oct 16;14:410. (PMID: 26474852)
Adm Policy Ment Health. 2011 Mar;38(2):65-76. (PMID: 20957426)
PLoS One. 2022 Oct 20;17(10):e0275822. (PMID: 36264996)
PLoS Med. 2019 Dec 13;16(12):e1002992. (PMID: 31834890)
PLoS One. 2015 Aug 14;10(8):e0135112. (PMID: 26275231)
BMC Public Health. 2017 May 18;17(1):470. (PMID: 28521798)
Pathogens. 2023 Mar 01;12(3):. (PMID: 36986323)
تواريخ الأحداث: Date Created: 20240719 Latest Revision: 20240721
رمز التحديث: 20240721
مُعرف محوري في PubMed: PMC11259306
DOI: 10.1371/journal.pgph.0003476
PMID: 39028699
قاعدة البيانات: MEDLINE
الوصف
تدمد:2767-3375
DOI:10.1371/journal.pgph.0003476